Vertical bone augmentation with fluvastatin in an injectable delivery system: A rat study

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Objectives: HMG-CoA reductase inhibitors (statins) are widely used for hyperlipidemia. Previous studies demonstrate that statins stimulate bone morphogenetic protein-2 (BMP-2) expression and lead to bone formation. The aim of this study was to evaluate whether percutaneously injected statin with a novel statin delivery system achieved vertical bone augmentation. Material and methods: As experimental groups, atelocollagen-α-tricalcium phosphate (αTCP) composites containing 3.3 mg (low dose) or 6.7 mg (high dose) of fluvastatin were injected (one shot) subcutaneously over the calvarial periosteum of rats. The animals were then sacrificed 1, 2, and 4 weeks after injection. Vertically augmented bone was assessed by histomorphometric procedures, i.e., by measuring new bone thickness (NBT) and bone density (BD). Results: In control groups, no newly formed bone could be seen over the calvarial bone. In the experimental groups, in contrast, a large amount of newly formed bone could be seen over the preexisting calvarial bone. The newly formed bone was seen to be in direct contact with the preexisting bone. During the entire observation, significant NBT was observed in the experimental groups (P<0.05). At the final stage of observation (4 weeks), NBT was 66.7% (low-dose group) and 59.7% (high-dose group), while they were from 1% to 16.3% in the control groups. In the experimental groups, BD significantly increased in a time-dependent manner. Conclusion: Percutaneously applied fluvastatin (one shot) with a composite of αTCP and collagen has great potential to augment the height of the bone.

Original languageEnglish
Pages (from-to)756-760
Number of pages5
JournalClinical Oral Implants Research
Volume20
Issue number8
DOIs
Publication statusPublished - Aug 1 2009

Fingerprint

fluvastatin
Bone and Bones
Injections
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Bone Density
Observation

All Science Journal Classification (ASJC) codes

  • Oral Surgery

Cite this

@article{1ae4b58375454167887fb75d9ee881fc,
title = "Vertical bone augmentation with fluvastatin in an injectable delivery system: A rat study",
abstract = "Objectives: HMG-CoA reductase inhibitors (statins) are widely used for hyperlipidemia. Previous studies demonstrate that statins stimulate bone morphogenetic protein-2 (BMP-2) expression and lead to bone formation. The aim of this study was to evaluate whether percutaneously injected statin with a novel statin delivery system achieved vertical bone augmentation. Material and methods: As experimental groups, atelocollagen-α-tricalcium phosphate (αTCP) composites containing 3.3 mg (low dose) or 6.7 mg (high dose) of fluvastatin were injected (one shot) subcutaneously over the calvarial periosteum of rats. The animals were then sacrificed 1, 2, and 4 weeks after injection. Vertically augmented bone was assessed by histomorphometric procedures, i.e., by measuring new bone thickness (NBT) and bone density (BD). Results: In control groups, no newly formed bone could be seen over the calvarial bone. In the experimental groups, in contrast, a large amount of newly formed bone could be seen over the preexisting calvarial bone. The newly formed bone was seen to be in direct contact with the preexisting bone. During the entire observation, significant NBT was observed in the experimental groups (P<0.05). At the final stage of observation (4 weeks), NBT was 66.7{\%} (low-dose group) and 59.7{\%} (high-dose group), while they were from 1{\%} to 16.3{\%} in the control groups. In the experimental groups, BD significantly increased in a time-dependent manner. Conclusion: Percutaneously applied fluvastatin (one shot) with a composite of αTCP and collagen has great potential to augment the height of the bone.",
author = "Yohei Jinno and Yasunori Ayukawa and Yoichiro Ogino and Atsuta Ikiru and Yoshihiro Tsukiyama and Kiyoshi Koyano",
year = "2009",
month = "8",
day = "1",
doi = "10.1111/j.1600-0501.2008.01665.x",
language = "English",
volume = "20",
pages = "756--760",
journal = "Clinical Oral Implants Research",
issn = "0905-7161",
publisher = "Blackwell Munksgaard",
number = "8",

}

TY - JOUR

T1 - Vertical bone augmentation with fluvastatin in an injectable delivery system

T2 - A rat study

AU - Jinno, Yohei

AU - Ayukawa, Yasunori

AU - Ogino, Yoichiro

AU - Ikiru, Atsuta

AU - Tsukiyama, Yoshihiro

AU - Koyano, Kiyoshi

PY - 2009/8/1

Y1 - 2009/8/1

N2 - Objectives: HMG-CoA reductase inhibitors (statins) are widely used for hyperlipidemia. Previous studies demonstrate that statins stimulate bone morphogenetic protein-2 (BMP-2) expression and lead to bone formation. The aim of this study was to evaluate whether percutaneously injected statin with a novel statin delivery system achieved vertical bone augmentation. Material and methods: As experimental groups, atelocollagen-α-tricalcium phosphate (αTCP) composites containing 3.3 mg (low dose) or 6.7 mg (high dose) of fluvastatin were injected (one shot) subcutaneously over the calvarial periosteum of rats. The animals were then sacrificed 1, 2, and 4 weeks after injection. Vertically augmented bone was assessed by histomorphometric procedures, i.e., by measuring new bone thickness (NBT) and bone density (BD). Results: In control groups, no newly formed bone could be seen over the calvarial bone. In the experimental groups, in contrast, a large amount of newly formed bone could be seen over the preexisting calvarial bone. The newly formed bone was seen to be in direct contact with the preexisting bone. During the entire observation, significant NBT was observed in the experimental groups (P<0.05). At the final stage of observation (4 weeks), NBT was 66.7% (low-dose group) and 59.7% (high-dose group), while they were from 1% to 16.3% in the control groups. In the experimental groups, BD significantly increased in a time-dependent manner. Conclusion: Percutaneously applied fluvastatin (one shot) with a composite of αTCP and collagen has great potential to augment the height of the bone.

AB - Objectives: HMG-CoA reductase inhibitors (statins) are widely used for hyperlipidemia. Previous studies demonstrate that statins stimulate bone morphogenetic protein-2 (BMP-2) expression and lead to bone formation. The aim of this study was to evaluate whether percutaneously injected statin with a novel statin delivery system achieved vertical bone augmentation. Material and methods: As experimental groups, atelocollagen-α-tricalcium phosphate (αTCP) composites containing 3.3 mg (low dose) or 6.7 mg (high dose) of fluvastatin were injected (one shot) subcutaneously over the calvarial periosteum of rats. The animals were then sacrificed 1, 2, and 4 weeks after injection. Vertically augmented bone was assessed by histomorphometric procedures, i.e., by measuring new bone thickness (NBT) and bone density (BD). Results: In control groups, no newly formed bone could be seen over the calvarial bone. In the experimental groups, in contrast, a large amount of newly formed bone could be seen over the preexisting calvarial bone. The newly formed bone was seen to be in direct contact with the preexisting bone. During the entire observation, significant NBT was observed in the experimental groups (P<0.05). At the final stage of observation (4 weeks), NBT was 66.7% (low-dose group) and 59.7% (high-dose group), while they were from 1% to 16.3% in the control groups. In the experimental groups, BD significantly increased in a time-dependent manner. Conclusion: Percutaneously applied fluvastatin (one shot) with a composite of αTCP and collagen has great potential to augment the height of the bone.

UR - http://www.scopus.com/inward/record.url?scp=67650902024&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67650902024&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0501.2008.01665.x

DO - 10.1111/j.1600-0501.2008.01665.x

M3 - Article

C2 - 19302395

AN - SCOPUS:67650902024

VL - 20

SP - 756

EP - 760

JO - Clinical Oral Implants Research

JF - Clinical Oral Implants Research

SN - 0905-7161

IS - 8

ER -